Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
Clinical trial NCT05253131 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT05253131
- Sponsor
- University of Alabama at Birmingham
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-11-15
- Primary completion
- 2031-11-15
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.